Novel and emerging prebiotics: Advances and opportunities

dc.contributor.authorCardoso, Beatriz B.por
dc.contributor.authorAmorim, Cláudiapor
dc.contributor.authorSilvério, Sara Isabel Cruzpor
dc.contributor.authorRodrigues, L. R.por
dc.date.accessioned2021-03-24T19:09:57Z
dc.date.embargo10000-01-01
dc.date.issued2021
dc.date.updated2021-03-07T17:33:01Z
dc.description.abstractConsumers are conscientiously changing their eating preferences toward healthier options, such as functional foods enriched with pre- and probiotics. Prebiotics are attractive bioactive compounds with multidimensional beneficial action on both human and animal health, namely on the gastrointestinal tract, cardiometabolism, bones or mental health. Conventionally, prebiotics are non-digestible carbohydrates which generally present favorable organoleptic properties, temperature and acidic stability, and are considered interesting food ingredients. However, according to the current definition of prebiotics, application categories other than food are accepted, as well as non-carbohydrate substrates and bioactivity at extra-intestinal sites. Regulatory issues are considered a major concern for prebiotics since a clear understanding and application of these compounds among the consumers, regulators, scientists, suppliers or manufacturers, health-care providers and standards or recommendation-setting organizations are of utmost importance. Prebiotics can be divided in several categories according to their development and regulatory status. Inulin, galactooligosaccharides, fructooligosaccharides and lactulose are generally classified as well established prebiotics. Xylooligosaccharides, isomaltooligosaccharides, chitooligosaccharides and lactosucrose are classified as “emerging” prebiotics, while raffinose, neoagaro-oligosaccharides and epilactose are “under development.” Other substances, such as human milk oligosaccharides, polyphenols, polyunsaturated fatty acids, proteins, protein hydrolysates and peptides are considered “new candidates.” This chapter will encompass actual information about the non-established prebiotics, mainly their physicochemical properties, market, legislation, biological activity and possible applications. Generally, there is a lack of clear demonstrations about the effective health benefits associated with all the non-established prebiotics. Overcoming this limitation willpor
dc.description.sponsorshipThe authors acknowledge the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UIDB/04469/2020 unit and BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte; and the projects COMPETE 2020 (POCI-01-0145-FEDER-006684), FoSynBio (POCI-01-0145-FEDER 029549) and NewFood (NORTE-01-0246-FEDER-000043). CA and BBC acknowledge their grants (UMINHO/BPD/4/2019 and SFRH/BD/132324/2017) from FCT.por
dc.distributioninternational
dc.identifier.citationCardoso, B. B., Amorim, C., Silvério, S. C., & Rodrigues, L. R. (2021). Chapter Two - Novel and emerging prebiotics: Advances and opportunities. In F. Toldrá (Ed.), Advances in Food and Nutrition Research (Vol. 95, pp. 41-95): Academic Press.
dc.identifier.doi10.1016/bs.afnr.2020.08.001por
dc.identifier.isbn9780128215203por
dc.identifier.issn1043-4526
dc.identifier.pmid33745516por
dc.identifier.urihttps://hdl.handle.net/1822/70994
dc.language.isoengpor
dc.peerreviewedyes
dc.publisherElsevier
dc.relationUIDB/04469/2020por
dc.relationUMINHO/BPD/4/2019por
dc.relationSFRH/BD/132324/2017por
dc.rightsrestrictedAccesspor
dc.subjectBiological activitypor
dc.subjectBioprocess productionpor
dc.subjectMarketpor
dc.subjectPrebioticpor
dc.subjectPrebiotic applicationspor
dc.titleNovel and emerging prebiotics: Advances and opportunitiespor
dc.typebookPartpor
dspace.entity.typePublicationen
oaire.citationEndPage95por
oaire.citationStartPage41por
oaire.citationVolume95por
sdum.export.identifier9003
sdum.journalAdvances in Food and Nutrition Research

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
CH0003_Rodrigues_ManuscriptRevised.pdf
Tamanho:
1.2 MB
Formato:
Adobe Portable Document Format